Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03835533 · ClinicalTrials.gov registry record · Phase 1
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
A Phase 1 study, sponsored by Parker Institute for Cancer Immunotherapy.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03835533 is a Phase 1 study that has completed, run by Parker Institute for Cancer Immunotherapy. The registered enrollment target is 43 participants.
The verdict
NCT03835533, a Phase 1 study, has completed, sponsored by Parker Institute for Cancer Immunotherapy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).
Interventions
- DRUG NKTR-214 (Cohort A)
- DRUG Nivolumab (Cohort A, B and C)
- RADIATION Stereotactic body radiation therapy (SBRT) (Cohort B)
- DRUG CDX-301 (Cohort B and C)
- DRUG Poly-ICLC (Cohort B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03835533
The ClinicalTrials.gov registry entry for NCT03835533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parker Institute for Cancer Immunotherapy, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which NKTR-214 (Cohort A) is the first listed.
NCT03835533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03835533 about?
NCT03835533 is a clinical study titled "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations". This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enza...
What is the current status of trial NCT03835533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2019-06-21. Estimated completion is 2022-10-03.
What interventions are being tested in trial NCT03835533?
The interventions under investigation include: NKTR-214 (Cohort A) (DRUG), Nivolumab (Cohort A, B and C) (DRUG), Stereotactic body radiation therapy (SBRT) (Cohort B) (RADIATION), CDX-301 (Cohort B and C) (DRUG), Poly-ICLC (Cohort B) (DRUG).
Who is sponsoring clinical trial NCT03835533?
This trial is sponsored by Parker Institute for Cancer Immunotherapy, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.